Targeting oxidative stress in embryonal rhabdomyosarcoma
Xiang Chen1, Elizabeth Stewart2, Anang A Shelat3
1Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Abstract:
Rhabdomyosarcoma is a soft-tissue sarcoma with molecular and cellular features of developing skeletal muscle. Rhabdomyosarcoma has two major histologic subtypes, embryonal and alveolar, each with distinct clinical, molecular, and genetic features. Genomic analysis shows that embryonal tumors have more structural and copy number variations than alveolar tumors. Mutations in the RAS/NF1 pathway are significantly associated with intermediate- and high-risk embryonal rhabdomyosarcomas (ERMS). In contrast, alveolar rhabdomyosarcomas (ARMS) have fewer genetic lesions overall and no known recurrently mutated cancer consensus genes. To identify therapeutics for ERMS, we developed and characterized orthotopic xenografts of tumors that were sequenced in our study. High-throughput screening of primary cultures derived from those xenografts identified oxidative stress as a pathway of therapeutic relevance for ERMS.
Insights
Rhabdomyosarcoma, a soft-tissue cancer, presents distinct subtypes with varying genetic profiles. Oxidative stress emerges as a key therapeutic target for embryonal rhabdomyosarcoma (ERMS).
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Rhabdomyosarcoma is a soft-tissue sarcoma originating from developing skeletal muscle.
- It comprises two main subtypes: embryonal rhabdomyosarcoma (ERMS) and alveolar rhabdomyosarcoma (ARMS), each with unique clinical, molecular, and genetic characteristics.
Purpose of the Study:
- To investigate the genomic landscape of ERMS and ARMS.
- To identify potential therapeutic targets for ERMS by developing and characterizing orthotopic xenografts.
Main Methods:
- Genomic analysis was performed on ERMS and ARMS tumors.
- Orthotopic xenografts were established from ERMS tumors.
- Primary cultures from xenografts underwent high-throughput screening.
Main Results:
- ERMS tumors exhibit more structural and copy number variations compared to ARMS.
- Mutations in the RAS/NF1 pathway are linked to intermediate- and high-risk ERMS.
- High-throughput screening identified oxidative stress as a relevant pathway for ERMS therapeutics.
Conclusions:
- Distinct genetic profiles differentiate ERMS and ARMS.
- Oxidative stress represents a promising therapeutic avenue for embryonal rhabdomyosarcoma.
